Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
about
Linkers Having a Crucial Role in Antibody-Drug ConjugatesProgress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery SystemsAntibody Drug Conjugates: Preclinical ConsiderationsA human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaA mechanistic tumor penetration model to guide antibody drug conjugate designIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CAMaytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubulesHigh-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and AlternativeLinked-in: design and efficacy of antibody drug conjugates in oncologyMirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer ModelsInvestigational antibody drug conjugates for solid tumors.Designing immunoconjugates for cancer therapy.Pharmacokinetic considerations for antibody drug conjugates.Advances in targeted therapeutic agents.Drug-conjugated antibodies for the treatment of cancer.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.Receptor-targeted drug delivery: current perspective and challenges.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.Strategies and challenges for the next generation of antibody-drug conjugates.Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates.Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
P2860
Q26752763-E0CD34E2-EE91-48DD-9045-BB4103E499DDQ26782485-029EA8BD-D819-4886-AB81-579ED21B0CFCQ27022321-31932B5C-0CDD-4B89-A00D-84DBB8F825DBQ28487973-BE5364A2-DF1E-4270-996A-83A623B5A12EQ28544636-3DDCF9BC-2BB8-49FF-9EDF-357EEA5F6225Q28660580-55E19B00-6097-46B0-99F9-8B2838D2E641Q30496972-E783BC90-4B0C-4DF6-A048-7CF5B32F0152Q30524836-B4FD5FEC-BA46-4C06-8F15-1758809851E0Q33873317-3F099730-476F-46B5-807F-75827EB8E55EQ34655256-30FC6F4C-AF11-4EA9-AD9E-8370B3920E0DQ34660299-99B8BABE-1F95-4C1E-B4EF-52C813D589F6Q35459059-AA2E712E-BF6F-4FFA-B86B-3CC547852032Q35892045-284EA387-320C-4B0C-A080-48468998CAFFQ37029370-1F60EBF5-E994-4A5D-BC68-FC4CF969F73BQ37447340-ABDC2704-1CF5-4135-B2D9-43AAEBB55B00Q37877745-639CCB2C-D058-4CC6-B580-B9F767570577Q38017203-8271C567-2B6D-4B87-93EB-9567B75D3782Q38022192-0D776FC7-C4D5-4CF7-A843-B1365AE3F014Q38029122-87AB85DB-9915-45D3-AE9D-15BBEED517A5Q38061647-637C0535-4B4D-4BC4-9BD0-910A57058CA5Q38068494-651A9627-AC1B-45D5-B86F-AE691AB95114Q38092648-D5A200A2-2B0A-4BF9-9B49-5132BDA7D188Q38202691-A4639AAB-2F90-494A-BF82-63D72B63FC6DQ38265617-376B7FB0-7ACD-43D3-BC8A-9F8360842D34Q38453769-30A162A9-6F32-4CC1-B7F1-E52B4D005EA4Q38579129-51354874-A558-4DA4-8643-D4C44FF040ABQ38624597-DCF20AD2-ECC8-4617-9A14-7C85D3E75E5EQ38648690-180EBDB3-6E9B-48ED-8A21-F7180BC05002Q38915595-83F38D51-8231-42EA-8280-9DB398BE3BA0Q38960075-A931B3D3-704C-4CF4-BFA2-E459481B2CE6Q39182945-C41862BD-5CAB-4A9D-B28C-EE8BE29CFF5CQ39210427-993C7D22-121C-46A8-8469-11056844F632Q39427630-070624DA-F1A4-4128-8AD0-C16CF70E889AQ39645683-5872752D-7AF9-410D-B753-133BC269B76DQ39815639-E3785382-2AA1-4661-98A4-EA1419A3076FQ40416482-D713577B-FA57-44B6-9D5D-8709BAA062A6Q41282870-38329C30-C726-44FD-90FC-A862B9F490ECQ42314398-FE9990E8-ACD4-4561-A47C-BD083CB64D7BQ43751494-978D30FB-C3AA-4FCA-9CAB-8DB5EAE58834Q46871150-007031A2-5745-48C4-92CB-17E1C96F19B9
P2860
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.
@en
Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.
@nl
type
label
Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.
@en
Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.
@nl
prefLabel
Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.
@en
Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.
@nl
P2093
P356
P1476
Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.
@en
P2093
Charlene Audette
Hans K Erickson
Kathleen Whiteman
Michele F Mayo
Rajeeva Singh
Sharon D Wilhelm
Wayne C Widdison
P356
10.1021/BC900315Y
P577
2010-01-01T00:00:00Z